Studies have showed that ANRIL mediates EMT by regulating downstream gene/protein in cancers, such as pancreatic cancer, laryngeal squamous cell carcinoma and renal cell carcinoma [30–32]. Here, CDKN2B-AS1 is linked to renal cell carcinoma.